Dr. Zohour Anouassi is a PGY1 Pharmacy Resident at Cleveland Clinic Abu Dhabi (CCAD) She completed her pharmacy education at the University of Sharjah and then pursued a Masters of Health Economics at Sorbonne University Abu Dhabi. During her residency...
thus far she has worked closely with her Cardiology rotation preceptor Bassam Atallah, PharmD, MS, BCPS-AQ Cardiology, FHFSA. Zohour completed one cardiology rotation and will also have another elective rotation in CHF transitionS of care. She has also worked on several....
cardiology related projects, including a protocol for eptifibatide use, dofetilide education, and has recently contributed to the Cardiology PRN newsletter on the topic of antithrombotic management post TAVR. Her residency research project is in the area of the appropriate....
use of the direct oral anticoagulants in the Middle East gulf region. She is also looking forward to participate in the upcoming heart failure academy for pharmacists, a unique 2 weeks didactic and experiential program established at CCAD. Zohour is determined to continue...
progressing in the field of clinical pharmacy and particularly in the field of cardiology pharmacotherapy. She is motivated and enthusiastic to help advance clinical pharmacy in the UAE.
SGLT-2 Inhibitors have quickly become one of the most talked-about pharmacotherapeutic classes in medicine. Let’s take a step back and understand how we got to this point and how you can use these agents in practice.
We can thank the -flozins for all of the wonderful data we now have with antihyperglycemic and their role in the prevention and treatment of CV disease. Since 2008, the FDA now requires cardiovascular outcomes trials based on these agents being linked to undesirable CV outcomes.
Cardiovascular disease is a global epidemic. Prevention is key. But we also need therapeutics for preventing recurrent CV disease as well.